Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients

Table 4 Comparison of vascular density in the shallow capillary plexus between the two groups (mean ± SD, %)

Groups	Before treatment	1 mo after treatment	3 mo after treatment
Fovea
Compaq group (n = 48)	20.64 ± 4.40	20.30 ± 3.95	20.28 ± 3.77
Ranibizumab group (n = 48)	20.90 ± 4.83	20.48 ± 4.20	20.37 ± 4.14
t value	-0.276	-0.216	-0.111
P value	0.783	0.829	0.912
Parafovea
Compaq group (n = 48)	38.56 ± 4.82	38.10 ± 4.50	37.73 ± 4.72
Ranibizumab group (n = 48)	39.10 ± 5.57	38.67 ± 5.53	38.38 ± 5.28
t value	-0.508	-0.554	-0.636
P value	0.613	0.581	0.526
Overall macular area
Compaq group (n = 48)	35.74 ± 5.10	35.43 ± 4.85	34.92 ± 5.51
Ranibizumab group (n = 48)	36.30 ± 5.34	35.67 ± 5.11	34.58 ± 5.18
t value	-0.525	-0.236	0.311
P value	0.601	0.814	0.756